Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W LubliniefiledCriticalUniwersytet Medyczny W Lublinie
Priority to PL419074ApriorityCriticalpatent/PL235217B1/en
Publication of PL419074A1publicationCriticalpatent/PL419074A1/en
Publication of PL235217B1publicationCriticalpatent/PL235217B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Przedmiotem zgłoszenia jest magnofloryna do zastosowania w leczeniu chorób przebiegających z zaburzeniami pamięci, zwłaszcza w leczeniu upośledzenia pamięci. Przedmiotem zgłoszenia jest także zastosowanie magnofloryny do wytwarzania preparatu farmaceutycznego do leczenia chorób przebiegających z zaburzeniami pamięci zwłaszcza do leczenia upośledzenia pamięci.The subject of the application is magnoflorin for use in the treatment of diseases with memory impairment, especially in the treatment of memory impairment. The subject of the application is also the use of magnoflorin for the production of a pharmaceutical preparation for the treatment of diseases with memory disorders, especially for the treatment of memory impairment.
PL419074A2016-10-112016-10-11Medical application of magnoflorine
PL235217B1
(en)
A PHARMACEUTICAL COMPOSITION CONTAINING ERYTHROPOIETIN AND CEPHTRIACONE AND ITS USE IN THE PRODUCTION OF A DRUG FOR THE TREATMENT OF PARKINSON'S DISEASE.